View Older Stories View More Recent Stories

Jun 4, 2025 05:09AM RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
Jun 3, 2025 09:29AM RBC Capital: 'What's Regeneron Pharma's (REGN) Best Next Move'
Jun 3, 2025 08:18AM UBS Reiterates Neutral Rating on Regeneron Pharma (REGN)
Jun 2, 2025 09:36AM RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
Jun 2, 2025 09:09AM Regeneron Pharma (REGN) PT Lowered at Bernstein Following a 'Disappointing Result'
Jun 2, 2025 08:45AM TD Cowen on Regeneron Pharma (REGN): 'LIBTAYO Could Become the Standard of Care'
Jun 2, 2025 08:28AM Truist on Regeneron Pharma (REGN): 'We Could See Stock Trading Sideways Near-Term'
Jun 2, 2025 08:10AM BMO Capital Comments on Regeneron Pharma (REGN): 'COURAGE Data/Obesity License Move REGN Forward'
Jun 2, 2025 07:38AM Regeneron Pharma (REGN) PT Lowered at BMO Capital as 'Updated Model Reflects Conservatism'
Jun 2, 2025 07:07AM Regeneron (REGN) Announces In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
Jun 2, 2025 07:00AM Regeneron (REGN) Reports Interim Results from Ongoing Phase 2 COURAGE Trial
May 30, 2025 12:38PM RBC Capital Downgrades Regeneron Pharma (REGN) to Sector Perform
May 30, 2025 10:12AM Raymond James Reiterates Market Perform Rating on Regeneron Pharma (REGN)
May 30, 2025 10:04AM Guggenheim Reiterates Buy Rating on Regeneron Pharma (REGN)
May 30, 2025 09:27AM Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
May 30, 2025 09:21AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
May 30, 2025 08:39AM Oppenheimer Reiterates Outperform Rating on Regeneron Pharma (REGN)
May 30, 2025 06:57AM Regeneron (REGN) Reports Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
May 30, 2025 06:48AM Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)
May 29, 2025 09:17AM RBC Capital Previews Regeneron Pharma (REGN): 'Deep Dive Suggests Plenty Of Reasons For Optimism'
May 27, 2025 08:42AM RBC Capital: Regeneron Pharma (REGN) Could Soar on Eylea Spin
May 24, 2025 10:00PM What can get the U.S. large-cap pharma sector to work?
May 22, 2025 05:06PM Regeneron (REGN) announces initial results from Phase 1b of linvoseltamab
May 19, 2025 07:06AM Regeneron (REGN) to Acquire 23andMe in Court-Supervised Sale
May 15, 2025 02:04PM Regeneron (REGN) Prevails over Amgen (AMGN) in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
May 14, 2025 05:01AM Citi Upgrades Regeneron Pharma (REGN) to Buy
May 1, 2025 09:35AM Regeneron (REGN) updates data from oncology and hematology portfolio
Apr 30, 2025 09:39AM Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
Apr 29, 2025 06:32AM Regeneron (REGN) Misses Q1 EPS by 26c
Apr 28, 2025 07:02AM Regeneron (REGN) Announces Lynozyfic Approved in the EU for the Treatment of Relapsed/Refractory Multiple Myeloma
Apr 23, 2025 06:05AM Regeneron Pharma (REGN) PT Lowered to $975 at Truist Securities
Apr 22, 2025 08:09AM Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
Apr 22, 2025 07:23AM Cantor Fitzgerald Assumes Regeneron Pharma (REGN) at Overweight
Apr 21, 2025 10:40AM CFRA Downgrades ABB LTD (ABBN:SW) (ABB) to Hold
Apr 17, 2025 07:03AM Regeneron (REGN): EYLEA HD Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Apr 10, 2025 07:10AM Regeneron Pharma (REGN) PT Lowered to $940 at Guggenheim
Apr 10, 2025 05:32AM Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
Apr 3, 2025 06:29AM Regeneron Pharma (REGN) PT Lowered to $979 at Bernstein Amid 'Eylea Headwinds'
Apr 1, 2025 10:00AM RBC makes changes to its flagship 'Top 30 Global Ideas for 2025' list
Mar 28, 2025 02:34PM Regeneron (REGN, Sanofi (SNY): Dupixent Approved as the First-ever Biologic Medicine in Japan for Patients with COPD
Mar 26, 2025 09:45AM Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
Mar 15, 2025 04:00AM How could tariffs shake up the pharma sector?
Mar 14, 2025 11:21AM Regeneron (REGN) Quickly Falls 1.6%, Weakness Said Tied To Negative Ruling
Mar 10, 2025 04:48PM REGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities
Mar 10, 2025 04:00PM FINAL REMINDER REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Regeneron Pharmaceuticals, Inc. Investors to Participate in the Class Action Lawsuit
Mar 10, 2025 01:49PM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Mar 9, 2025 04:00PM FINAL REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Regeneron Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit
Mar 9, 2025 12:30PM REGN IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in S
View More Recent Stories View Older Stories